Skip to main content
. Author manuscript; available in PMC: 2014 Aug 1.
Published in final edited form as: Inflamm Bowel Dis. 2013 Aug;19(9):1983–1989. doi: 10.1097/MIB.0b013e31829292f7

Figure 3. Specific blockade of VEGFR-3 increases lymphatic vessel abnormalities in the Il10−/− mouse model of IBD.

Figure 3

(A) Colon sections of 8-weeks old C3Bir-Il10−/− mice were immunostained for LYVE1 (red) and counterstained with hematoxylin. While control mouse colons contained moderately enlarged lymphatic vessels, anti-VEGFR-3 treated mice contained larger areas with dense, enlarged and irregularly shaped lymphatic vessels, surrounded by the edematous tissue. Three representative images are shown, scale bar: 100 µm. Inflammatory changes of lymphatic vessels were evaluated by inspecting the colon tissue for the presence of large and tortuous vessels (B), by determining the area covered by lymphatic vessels in inflamed tissue (C), and by measuring the size of the lymphatic vessels in the inflamed tissue (D). (E) Edema was evaluated by measuring the width of the colon submucosa. (t-test *p ≤ 0.05, **p ≤ 0.01; n=7–8).